Curcumin Attenuates Urinary Excretion of Albumin in Type II Diabetic Patients with Enhancing Nuclear Factor Erythroid-Derived 2-Like 2 (Nrf2) System and Repressing Inflammatory Signaling Efficacies

Abstract

Curcumin has a therapeutic potential in treating diabetic kidney disease (DKD) while potential mechanisms underlining this beneficial effect remain to be elucidated. In the present study, curcumin intervention was performed in patients with Type II diabetes mellitus (T2DM) by oral intake of curcumin at the dose of 500 mg/day for a period of 15–30 days. Nephritic excretion of urinary micro-albumin (U-mAlb) and blood metabolic indexes were assessed before and after this intervention. In addition, the lipid oxidation index, malondialdehyde (MDA) in plasma and the status of anti-oxidative Nrf2 system in blood lymphocytes were measured. The effect of curcumin on inflammation was assessed by measuring plasma lipopolysaccharide (LPS) content and inflammatory signaling protein in blood lymphocytes. A self-comparison method was used for assessing statistical significances of these measurements. Here we show that curcumin intervention markedly attenuated U-mAlb excretion without affecting metabolic control of participated patients. In addition, curcumin reduced plasma MDA level with enhanced the Nrf2 system specifically regulated protein, NAD(P)H quinone oxidoreductase 1 (NQO-1) together with other anti-oxidative enzymes in patients’ blood lymphocytes. Furthermore, we observed reduced plasma LPS content and increased IκB, an inhibitory protein on inflammatory signaling in patient’s lymphocytes after curcumin administration. Finally, several gut bacterials important for maintaining gut barrier integrity and function were upregulated by curcumin.

In conclusion, short-term curcumin intervention ablates DKD progress with activating Nrf2 anti-oxidative system and anti-inflammatory efficacies in patients with T2DM.

Key words

curcumin - diabetic nephropathy - Nrf2 - gut microbiota - lymphocyte

• References

• 1 Mora-Fernandez C, Dominguez-Pimentel V, de Fuentes MM et al. Diabetic kidney disease: from physiology to therapeutics. J Physiol 2014; 592: 3997-4012
• 2 Arora MK, Singh UK. Oxidative stress: meeting multiple targets in pathogenesis of diabetic nephropathy. Curr Drug Targets 2014; 15: 531-538
• 3 Tan SM, de Haan JB. Combating oxidative stress in diabetic complications with Nrf2 activators: how much is too much?. Redox Rep 2014; 19: 107-117
• 4 Impellizzeri D, Esposito E, Attley J et al. Targeting inflammation: new therapeutic approaches in chronic kidney disease (CKD). Pharmacol Res 2014; 81: 91-102
• 5 Yu Z, Shao W, Chiang Y et al. Oltipraz upregulates the nuclear factor (erythroid-derived 2)-like 2 [corrected](NRF2) antioxidant system and prevents insulin resistance and obesity induced by a high-fat diet in C57BL/6J mice. Diabetologia 2011; 54: 922-934
• 6 Velmurugan GV, Sundaresan NR, Gupta MP et al. Defective Nrf2-dependent redox signalling contributes to microvascular dysfunction in type 2 diabetes. Cardiovasc Res 2013; 100: 143-150
• 7 Xu X, Luo P, Wang Y et al. Nuclear factor (erythroid-derived 2)-like 2 (NFE2L2) is a novel therapeutic target for diabetic complications. J Int Med Res 2013; 41: 13-19
• 8 Tan SM, Sharma A, Stefanovic N et al. Derivative of Bardoxolone Methyl, dh404, in an Inverse Dose-Dependent Manner Lessens Diabetes-Associated Atherosclerosis and Improves Diabetic Kidney Disease. Diabetes 2014; 63: 3091-3103
• 9 Cui W, Bai Y, Miao X et al. Prevention of diabetic nephropathy by sulforaphane: possible role of Nrf2 upregulation and activation. Oxid Med Cell Longev 2012; 2012: 821936
• 10 He HJ, Wang GY, Gao Y et al. Curcumin attenuates Nrf2 signaling defect, oxidative stress in muscle and glucose intolerance in high fat diet-fed mice. World J Diabetes 2012; 3: 94-104
• 11 Khajehdehi P, Pakfetrat M, Javidnia K et al. Oral supplementation of turmeric attenuates proteinuria, transforming growth factor-beta and interleukin-8 levels in patients with overt type 2 diabetic nephropathy: a randomized, double-blind and placebo-controlled study. Scand J Urol Nephrol 2011; 45: 365-370
• 12 Soetikno V, Suzuki K, Veeraveedu PT et al. Molecular understanding of curcumin in diabetic nephropathy. Drug Discov Today 2013; 18: 756-763
• 13 Gupta SC, Patchva S, Aggarwal BB. Therapeutic roles of curcumin: lessons learned from clinical trials. AAPS J 2013; 15: 195-218
• 14 Meng B, Li J, Cao H. Antioxidant and antiinflammatory activities of curcumin on diabetes mellitus and its complications. Curr Pharm Des 2013; 19: 2101-2113
• 15 Weisberg SP, Leibel R, Tortoriello DV. Dietary curcumin significantly improves obesity-associated inflammation and diabetes in mouse models of diabesity. Endocrinology 2008; 149: 3549-3558
• 16 Roshan B, Stanton RC. A story of microalbuminuria and diabetic nephropathy. J Nephropathol 2013; 2: 234-240
• 17 Dall TM, Narayan KM, Gillespie KB et al. Detecting type 2 diabetes and prediabetes among asymptomatic adults in the United States: modeling American Diabetes Association versus US Preventive Services Task Force diabetes screening guidelines. Popul Health Metr 2014; 12: 12
• 18 Yu Z, Morrison M. Improved extraction of PCR-quality community DNA from digesta and fecal samples. Biotechniques 2004; 36: 808-812
• 19 Suresh BP, Srinivasan K. Amelioration of renal lesions associated with diabetes by dietary curcumin in streptozotocin diabetic rats. Mol Cell Biochem 1998; 181: 87-96
• 20 Srinivasan M. Effect of curcumin on blood sugar as seen in a diabetic subject. Indian J Med Sci 1972; 26: 269-270
• 21 Chuengsamarn S, Rattanamongkolgul S, Phonrat B et al. Reduction of atherogenic risk in patients with type 2 diabetes by curcuminoid extract: a randomized controlled trial. J Nutr Biochem 2014; 25: 144-150
• 22 Soetikno V, Suzuki K, Veeraveedu PT et al. Molecular understanding of curcumin in diabetic nephropathy. Drug Discov Today 2013; 18: 756-763
• 23 Badal SS, Danesh FR. New insights into molecular mechanisms of diabetic kidney disease. Am J Kidney Dis 2014; 63: S63-S83
• 24 Nymark M, Pussinen PJ, Tuomainen AM et al. Serum lipopolysaccharide activity is associated with the progression of kidney disease in finnish patients with type 1 diabetes. Diabetes Care 2009; 32: 1689-1693
• 25 Bereswill S, Munoz M, Fischer A et al. Anti-inflammatory effects of resveratrol, curcumin and simvastatin in acute small intestinal inflammation. PLoS One 2010; 5: e15099
• 26 Cox AJ, West NP, Cripps AW.. Obesity, inflammation, and the gut microbiota. Lancet Diabetes Endocrinol 2014; 5: 437-445
• 27 Khan MT, Nieuwdorp M, Backhed F.. Microbial Modulation of Insulin Sensitivity. Cell Metab 2014; 20: 753-760
• 28 Stenman LK, Waget A. Garret C, Klopp P, Burcelin R, Lahtinen S. Potential probiotic Bifidobacterium animalis ssp. lactis 420 prevents weight gain and glucose intolerance in diet-induced obese mice. Benef Microbes 2014; 5: 437-445
• 29 Zhang Y, Guo X, Guo J et al. Lactobacillus casei reduces susceptibility to type 2 diabetes via microbiota-mediated body chloride ion influx. Sci Rep 2014; 4: 5654
• 30 Gomes AC, Bueno AA. de Souza RG, Mota JF. Gut microbiota, probiotics and diabetes. Nutr J 2014; 13: 60
• 31 Ma J, Chadban SJ, Zhao CY et al. TLR4 activation promotes podocyte injury and interstitial fibrosis in diabetic nephropathy. PLoS One 2014; 9: e97985
• 32 Yang M, Gan H, Shen Q et al. Proinflammatory CD14+CD16+ monocytes are associated with microinflammation in patients with type 2 diabetes mellitus and diabetic nephropathy uremia. Inflammation 2012; 35: 388-396